EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%

Sezer, A.Kilickap, S.Gumus, M.Bondarenko, I.Ozguroglu, M.Gogishvili, M.Turk, H. M.2024-06-122024-06-1220200923-75341569-8041https://doi.org/10.1016/j.annonc.2020.08.2285https://hdl.handle.net/20.500.14551/25573ESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORK[Abstract Not Available]en10.1016/j.annonc.2020.08.2285info:eu-repo/semantics/openAccess[No Keywords]EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%Conference Object31S1182S1183Q1WOS:000573469102683